In this infographic we summarize the clinical candidates reported by the WHO – indicating which diseases they are active (or possibly active) against, whether they’re considered innovative and which Phase the trials are currently in.
Browsing: Bacterial > Tuberculosis
The WHO’s most recent global tuberculosis report has stated that the burden of TB is still high, with gaps in diagnosis and growing drug-resistance posing challenges on our way to ending this epidemic.
A new article has assessed the market penetration of a molecular TB test, Xpert MTB/RIF®, revealing that implementation in high-burden countries has progressed well, but there is more to be done.
We speak to Rebecca Prevots, from the National Institute of Allergy and Infectious Diseases, who discusses her current research projects, the importance of epidemiology in studying infectious diseases and also the challenges this field currently faces.
Virtual screening (VS) is powerful tool in discovering molecular inhibitors that are most likely to bind to drug targets of interest. Here, the authors introduce a novel VS approach, so-called ‘tailored-pharmacophore’, in order to explore inhibitors that overcome drug resistance.
A new mathematical modelling study has estimated the mortality rates of TB in the pediatric population, producing the first ever estimate for infants under 5 years of age.
In this interview with Patrick Harris, from the University of Queensland, we discuss his role in setting up and co-ordinating the MERINO trial, and his research on the use of genomics in clinical microbiology.
Researchers have discovered that cell division sites in mycobacteria are correlated with inherited wave-like morphological landmarks on the cell surface.